Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

NCT00262288 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Genetic Disorders

Interventions

DRUG: i.v. recombinant human C1 inhibitor

Sponsor

Pharming Technologies B.V.